591 patients with a history of coronary heart disease had one or more biochemical markers of tobacco smoking measured. 26% were self reported smokers and a further 40/0 were apparent 'smoking deceivers'. The urinary nicotine metabolite concentration is an excellent marker for tobacco smoking; breath CO would be a suitable alternative for busy clinics. Half the patients were subjected to regular advice on risk factor management but there was no evidence that this contributed effectively to smoking cessation. Overall smoking cessation rate was poor.
SUMMARY. 591 patients with a history of coronary heart disease had one or more biochemical markers of tobacco smoking measured. 26% were self reported smokers and a further 40/0 were apparent 'smoking deceivers'. The urinary nicotine metabolite concentration is an excellent marker for tobacco smoking; breath CO would be a suitable alternative for busy clinics. Half the patients were subjected to regular advice on risk factor management but there was no evidence that this contributed effectively to smoking cessation. Overall smoking cessation rate was poor.
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Northern Ireland has a particularly high prevalence of coronary heart disease.' Various studies have indicated the risk associated with tobacco smoking/ and the benefits of smoking cessation! on coronary heart disease. Large numbers of individuals with coronary heart disease, however, continue to smoke. We report here our findings on tests of smoking activity in a group of patients with coronary heart disease who were followed up for 2 years. Our objectives were to define the most useful test for smoking status in terms of diagnostic efficiency and to monitor the outcome of advice to smokers in terms of cessation rate.
SUBJECTS
Patients with a history of coronary heart disease took part in this study. From a general practice data base, 688 patients were identified: of these 63 failed to complete the initial protocol and a further 34 did not meet the minimum entry criterion for this study which was the baseline measurement of urinary nicotine metabolite. This left 591 subjects (357 men, 234 women) who had a combination of biochemical tests for markers of tobacco smoking which included the measurement of urinary nicotine metabolite, breath carbon monoxide and serum thiocyanate. One hundred Correspondence to: G P R Archbold. and fifty-three were self reported smokers [102 men, 51 women; mean age 61'9 years (range 40-74) 1of whom 123 smoked cigarettes (74 men, 49 women) and 30 smoked the pipe or cigars. They were not initially told the nature of the tests being performed. Each subject was assigned to one of two groups by a computer programme generated random allocation of numbers. The allocations were placed in sealed envelopes which were opened only after completion of the initial observations. The non-intervention group (300 subjects) received 'ordinary' NHS care (review by patient request) and the intervention group (291 subjects) were visited by a health visitor who gave advice on risk factor management once every 4 months for 2 years. All 591 participating patients were invited to a 2 year review (544 attended) at which breath CO was measured. In addition, self reported smokers and those who had been defined as 'smoking deceiver' (on the basis of their baseline tests) were asked to provide a random urine sample for nicotine metabolite estimation. Only 91 subjects (out of 160 who attended) fulfilled this re-screening obligation.
METHODS

Breath carbon monoxide (CO) was measured by a portable CO monitor (Model EC50 Micro
Smokerlyzer, Bedfont Technical Instruments Ltd, Kent, UK). The monitor was calibrated and standardized against control gas.
Serum thiocyanate was measured after the method of Butts et at," The method was adapted to the Cobas Fara centrifugal analyser. Standards were aqueous and controls were serum based. At levels of 120Iilllol/L and 240Iilllol/L the intrabatch coefficient of variation (CVs) were 11·611Jo and 6·6% and the interbatch CVs were 14·8% and 7· 9%, respectively.
Urinary nicotine metabolite was measured by radioimmunoassay (Diagnostic Products Corporation, Los Angeles, CA, USA). At levels of 700 ILg/L and 7000 ILg/L the intrabatch CVs were 8·9% and 11·5% and the interbatch CVs were 11·5% and 16'6%, respectively. Urinary nicotine metabolite levels were used with and without correction for the urinary creatinine level.
STATISTICS
Breath carbon monoxide and serum thiocyanate concentrations in non-smokers and smokers approximated to a normal distribution. Urinary nicotine metabolite and its creatinine ratio were log transformed before analysis.
Comparison between groups was by t-test.
RESULTS
Distributions of markers of tobacco smoking are shown in Fig. 1 Only readings from the digital display were used in this analysis. From the concentrations of the markers and especially of the urinary nicotine metabolite and its creatinine ratio we have identified a small subset of alleged non-smokers who had values above those conventionally associated with nonsmokers. We have ascribed these subjects to a group classified as 'smoking deceivers' and we have used the nicotine metabolite concentration and its creatinine ratio to give us a biochemical classification of smoking status in addition to accepting the status of those who reported a positive smoking history. We accept that this Ann C/in Biochem 1995: 32 introduces bias in that some individuals may have been misclassified by this process but misclassification also occurs with self reporting of smoking habit. If both urinary nicotine metabolite and its creatinine ratio were above the discrimination point (i.e. > 2SDs above the mean value for non-smokers) the self reported non-smoker was classified as a 'smoking deceiver': these subjects were not re-classified as smokers for data analysis. In 12 cases of self reported non-smoking either urinary nicotine metabolite (n = 4) or its creatinine ratio (n = 8), but not both, were above the discrimination level: these subjects were classified as non-smokers.
The concentrations of the markers were significantly higher in smokers than in nonsmokers, and within non-smokers those who were subject to passive inhalation of tobacco smoke had higher concentrations of urinary nicotine metabolite and its creatinine ratio (P<O·oool).
The sensitivities and specificities of the markers as determined from baseline measurements are shown in Table 2 at the selected discrimination points. At 2 year review, sensitivity and specificity of breath CO for non-smokers (n = 222) and smokers (n = 59) at 5 ppm was 98·2% and 81'4%, respectively. The concentrations of urinary nicotine metabolite (and its creatinine ratio) found in smokers at the 2 year review are shown in Table 3 .
Receiver operating characteristic (ROC) curves for the markers are shown in Fig. 2 . The curves illustrate the superior diagnostic efficiency of urinary nicotine metabolite measurement even when smoking status is defined by self report only ( Fig. 2a ).
At 2 year follow-up, 63 of the 123 cigarette smokers completed the re-screening protocol: 30 of these were intervention subjects and of these four had stopped smoking (confirmed by urinary nicotine metabolite concentration) and a further two said they had stopped but this was inconsistent with biochemical monitoring (i.e. they had become 'smoking deceivers'). Of the 33 usual care group, four had stopped smoking and one had become a 'smoking deceiver'. Overall the urinary nicotine metabolite concentrations were significantly reduced at 2 years (this compares with the claims of the group, 15 of whom said they had reduced tobacco consumption and nine of whom said they were smoking more).
In the group who were pipe or cigar smokers, 1 of the 17 followed-up by urinary nicotine metabolite concentration had become a 'smoking deceiver' (from the intervention group). Of the original group of 'smoking deceivers' , 11 were followed by urinary nicotine metabolite concentration: four were intervention group and of these two now admitted some form of smoking and seven were usual care and of these six now admitted smoking.
One non-smoker started smoking during the 2 year follow-up period (confirmed by urinary nicotine metabolite concentration). Over the 2 year follow-up of the 591 subjects in this study, nine smokers, two 'smoking deceivers' and 13 non-smokers died.
DISCUSSION
Serum and urinary cotinine levels have been found to be sensitive markers of tobacco smoking. In this study the commercial immunoassay used to measure 'cotinine' cross reacts significantly with 3 hydroxy cotinine and the recorded results describe nicotine metabolite rather than cotinine. The discrimination levels of breath CO and serum thiocyanate for non-smokers and smokers are comparable to other studies.":" The level for urinary nicotine metabolite is higher than for urinary cotinine-! and may reflect the specificity of the assay.
The correction of urinary nicotine metabolite for urinary creatinine in this study is done as a simple ratio; others have used regression adjustments for log transformed data.?
The superior diagnostic efficiency of urinary nicotine metabolite as a marker of tobacco smoking is confirmed by the ROC curves ( Fig. 2 ): there appears to be little to choose between urinary nicotine metabolite and the nicotine metabolite/creatinine ratio. Not all subjects, however, readily complied with the request for a random sample of urine and this would represent the only drawback to the test. Despite the problems encountered with one health visitor in reading the breath CO correctly, we feel that breath CO is an acceptable and practicable measurement and has the advantage of nearpatient testing. Serum thiocyanate is the least satisfactory test and requires an invasive procedure.
The finding that passive smokers had higher concentrations of urinary nicotine metabolite than true non-smokers confirms previous studies: 8, 10 breath CO and serum thiocyanate lack the analytical sensitivity to distinguish passive smoking. Woodward et al." found that, of the three markers (breath CO, serum thiocyanate and serum cotinine) only serum cotinine was able to distinguish passive smokers.
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The presence of a subgroup, among self reported non-smokers, with concentrations of smoking markers suggestive that, in fact, they were smokers has been reported by others l l , I2 and these subjects have been termed 'smoking deceivers'. Approximately 4070 of the total study population appear to be 'smoking deceivers' which is in line with other estimates.P'"
The Northern Ireland Health Survey!" showed that in the age range 12-64 years, 50% of the population had smoked at some time and 31070 were current smokers. The MONICA Study (Northern Ireland) indicates that 29% of men and 24% of women aged 45-64 are current smokers (JWG Yarrell, personal communication).
This study shows that 26% of patients (age range 40-74 years) with established angina continue to smoke (and a further 4% appear to be 'smoking deceivers').
These results emphasize the difficulty in achieving smoking cessation (both in control and intervention groups) even when the subjects have a life-threatening, smoking-related disease. Cessation rates were poor; a minor consolation was lower urinary nicotine metabolite concentrations at 2 year follow-up (Table 3) suggesting reduced absorption of nicotine for whatever reason (some subjects claimed to have reduced tobacco consumption but others had increased it). Differences in cotinine excretion for the same amount smoked may be related to nicotine yield of the cigarette, time since last smoke, and manner of smoking. 15 ,16 In the Scottish Heart Health Study'? subjects with known coronary heart disease had distorted reporting of smoking with greater smoke inhalation and higher concentrations of serum cotinine per stated cigarette consumed than other smokers.
Knowledge of the information that these biochemical tests provide could possibly contribute to a higher cessation rate. Confrontation of smokers and 'smoking deceivers' with their individual results may give incentive and encouragement to stop. On the other hand, it could simply encourage non-attendance at follow-up.
We conclude that the best test for smoking status in terms of diagnostic efficiency is the urinary nicotine metabolite concentration: in terms of practicability the breath CO concentration is an acceptable alternative. Smoking habits, however, are not easily changed even in risk factor intervention studies.
